Product Description
BAT1308 is a humanized anti-PD-1 monoclonal antibody candidate for treatment of solid tumors. A phase I clinical trial for BAT1308 as monotherapy in solid tumors is currently ongoing. Clinical strategies for BAT1308 will be in combination therapies, such as with BAT1706, an anti-VEGF monoclonal antibody, for non-small cell lung cancer, among many solid tumors. (Sourced from: https://www.bio-thera.com/plus/list.php?tid=54)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Biothera
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Cervical Cancer|Uterine Cancer
Phase 2: Oncology Solid Tumor Unspecified
Phase 1: Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05155722 |
BAT-1308-001-CR | P1 |
Completed |
Non-Small-Cell Lung Cancer|Hepatocellular Carcinoma|Cervical Cancer|Small Cell Lung Cancer |
2024-07-09 |
50% |
2025-12-11 |
Primary Completion Date|Primary Endpoints |
NCT06341114 |
BAT-8008-1308-001-CR | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2026-04-03 |
12% |
2025-12-11 |
Primary Endpoints|Treatments |
NCT06123884 |
BAT-1308-002-CR | P3 |
Recruiting |
Uterine Cancer|Cervical Cancer |
2026-09-01 |
42% |
2025-02-12 |
|
CTR20201105 |
CTR20201105 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2024-07-09 |
2025-11-09 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233723 |
CTR20233723 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-08-05 |
Patient Enrollment|Treatments|Trial Status |